Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI



Status:Completed
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:6/1/2018
Start Date:May 31, 2013
End Date:September 12, 2017

Use our guide to learn which trials are right for you!

Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Fulvestrant (Faslodex) Plus Everolimus in Post-Menopausal Patients With Hormone-Receptor Positive Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy

Post-menopausal women with hormone-receptor positive (HR+) metastatic breast cancer resistant
to aromatase inhibitor (AI) therapy will be randomized to receive Fulvestrant (Faslodex) with
Everolimus or Fulvestrant (Faslodex) with a placebo (no active ingredients).

Fulvestrant has demonstrated activity when used as first, second, or third line endocrine
therapy, making it an attractive therapy for combination with other agents. In addition, it
is commonly reserved for use following disease progression on AI therapy.

Everolimus is an orally administered drug that blocks a signaling pathway called "mTOR".
"mTOR" acts as a regulator for many processes in the body, including cell growth. Blocking
this pathway may have an effect on cell growth.

The combination of a novel class of agents (mTOR inhibitors) and an established standard
treatment for metastatic HR+ breast cancer may potentially increase the clinical benefit by
targeting multiple different biological pathways.

Breast cancer is the most commonly diagnosed malignancy in women worldwide. In the United
States, an estimated 230,480 new cases of invasive breast cancer were diagnosed in 2011, with
39,520 breast cancer deaths. In 40-80% of women with node-positive disease at diagnosis,
their breast cancer will recur. When distant metastases occur, median survival is 18 to 36
months from time of recurrence. Among the 60-70% of women with HR+ breast cancer, 40-60% of
them will benefit from endocrine therapy. Endocrine therapy has shown to yield similar
survival rates in hormone-sensitive disease as compared to chemotherapy; although response
rates are lower and responses develop more slowly. Endocrine therapy is considerably less
toxic than chemotherapy, and is therefore the preferred treatment option for patients with
HR+ disease.

Endocrine therapy represents the foundation of treatment for HR+ metastatic and locally
advanced breast cancer. Multiple compounds in varying classes exist, and those most widely
used include the selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs),
and the selective estrogen receptor down-regulators (SERDs). Although the utility of these
drugs is well established, as many as 50% of women with HR+ breast cancer will fail to
respond to endocrine treatment. Moreover, those who do respond will inevitably develop
acquired resistance.

Fulvestrant is the first drug which acts as a pure estrogen receptor (ER) antagonist without
known agonist effects. It competitively binds to the ERs with an approximately 100 times
greater affinity than that of tamoxifen. Fulvestrant promotes the degradation of ERs and
subsequently prevents ER-mediated gene transcription.

Everolimus (RAD001) is an oral derivative of rapamycin that is an m-TOR inhibitor. At
cellular and molecular levels, everolimus acts as a signal transduction inhibitor. Everolimus
selectively inhibits mTOR (mammalian target of rapamycin); a key and highly conserved
serine-threonine kinase which is present in all cells and is a central regulator of protein
synthesis and ultimately cell growth, cell proliferation, angiogenesis and cell survival.
mTOR is the only currently known target of everolimus.

In oncology, everolimus has been in clinical development since 2002 for patients with various
hematologic and non-hematologic malignancies as a single agent or in combination with
antitumor agents, including cytotoxic chemotherapeutic agents, targeted therapies, antibodies
and hormonal agents.

Patients will be randomized (1:1) to receive everolimus or placebo with fulvestrant after
consideration of stratification factors of performance status (0 vs. 1), measurable disease
(yes vs. no), and prior chemotherapy for metastatic disease (yes vs. no).

Patients will be evaluated for disease response every 12 weeks, and treated until disease
progression or unacceptable toxicity or withdrawal of consent for a maximum of 12 cycles (48
weeks).

Patients with no evidence of progressive disease who remain on study after completing 12
cycles are unblinded and continue to receive fulvestrant alone (if originally randomized to
placebo) or in combination with everolimus (if originally randomized to everolimus) at the
same dose and schedule. Patients will continue to be evaluated for disease response every 12
weeks and continue until disease progression or unacceptable toxicity.

Inclusion Criteria:

1. Signed informed consent.

2. ≥18 years.

3. ECOG Performance Status 0 or 1.

4. Histologically or cytologically confirmed adenocarcinoma of the breast.

5. Stage IV disease or inoperable locally advanced disease.

6. ER and/or PR-positive disease. Tumors must be HER-2/neu negative or equivocal.

7. Aromatase Inhibitor (AI) resistant, defined as:

- relapsed while receiving adjuvant therapy with an AI or,

- progressive disease while receiving an AI for metastatic disease

8. Received one prior cycle of fulvestrant within 28 days of randomization are eligible.

- ≥2 prior doses of fulvestrant are not eligible

9. Must be female and postmenopausal.

10. May have received ≤1 prior systemic chemotherapy regimen for metastatic disease.

11. Adequate organ function:

- Whole Blood Cells (WBC) ≥3.0 x 10⁹/L, Absolute neutrophil count (ANC) ≥1.5 x
10⁹/L and platelet count ≥100 x 10⁹/L

- hemoglobin ≥9 g/dL

- serum bilirubin ≤1.5 X ULN (Upper Limit of Normal)

- Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ≤2.5 X ULN (≤5
x ULN in patients with liver metastases)

- serum creatinine ≤1.5 X ULN

- serum albumin ≥3 g/dL

- fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fasting triglycerides
≤2.5 x ULN.

- Prothrombin time (PT) with international normalized ratio (INR) ≤1.5

12. May have measurable disease, non-measurable disease, or both.

13. Basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
within the past five years treated with curative intent. History of prior malignancy
are eligible if disease-free for >3 years.

Exclusion Criteria:

1. Major surgery or significant traumatic injury within 4 weeks of randomization or
patients that may require major surgery during the course of the study.

2. Investigational agents within 4 weeks of randomization.

3. Anticancer treatment within 4 weeks of randomization, with the following exceptions:

- Bisphosphonates or Zometa for bone metastases

- a GnRH analog is permitted if the patient had progressive disease on a GnRH
(Gonadotropin-Releasing Hormone) analog plus a SERM (Selective Estrogen Receptor
Modulators) or an AI; the GnRH analog may continue but the SERM or AI must be
discontinued.

4. Prior treatment with an mTOR inhibitor.

5. Receiving chronic, systemic treatment with corticosteroids or another
immunosuppressive agent ≥ 5 mg prednisone or equivalent daily.

6. Receive immunization with attenuated live vaccines within one week of randomization or
during the study period.

7. Current or a prior history of brain metastases or leptomeningeal disease. Must not
have rapidly progressive, life-threatening metastases.

8. Known hypersensitivity/history of allergic reactions attributed to compounds of
similar chemical or biologic composition to everolimus or fulvestrant.

9. Congenital or acquired immune deficiency at increased risk of infection.

10. Impairment of gastrointestinal function/disease that may significantly alter the
absorption of everolimus.

11. Active, bleeding diathesis.

12. History of any condition or uncontrolled intercurrent illness that in the opinion of
the local investigator might interfere with or limit the patient's ability to comply
with the protocol or pose additional or unacceptable risk to the patient.

13. Severe and/or uncontrolled medical conditions or other conditions that could affect
their participation in the study such as:

- Symptomatic congestive heart failure of New York Heart Association Class III or
IV

- Unstable angina pectoris, myocardial infarction within 6 months of randomization,
serious uncontrolled cardiac arrhythmia or any other clinically significant
cardiac disease

- History of symptomatic pulmonary disease or non-malignant pulmonary disease
requiring treatment.

- Uncontrolled diabetes as defined by fasting serum glucose >1.5 x ULN

- Active (acute or chronic) or uncontrolled severe infections

- Liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh Class
C).

Note: Detailed assessment of Hepatitis B/C medical history and risk factors must be done at
screening.
We found this trial at
25
sites
New York, New York 10003
?
mi
from
New York, NY
Click here to add this to my saved trials
3400 N Charles St
Baltimore, Maryland 21205
410-516-8000
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
3550 Jerome Avenue
Bronx, New York 10467
(718) 920-4321
Montefiore Medical Center As the academic medical center and University Hospital for Albert Einstein College...
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Ames, Iowa 50010
McFarland Clinic, PC It has been over 65 years since the founders of McFarland Clinic...
?
mi
from
Ames, IA
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48158
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Charleston, West Virginia 25304
?
mi
from
Charleston, WV
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Dallas, Texas 75390
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Dunmore, PA
Click here to add this to my saved trials
Green Bay, Wisconsin 54301
?
mi
from
Green Bay, WI
Click here to add this to my saved trials
Greenbrae, California 94904
?
mi
from
Greenbrae, CA
Click here to add this to my saved trials
Hershey, Pennsylvania 17033
?
mi
from
Hershey, PA
Click here to add this to my saved trials
1900 South Avenue
La Crosse, Wisconsin 54601
?
mi
from
La Crosse, WI
Click here to add this to my saved trials
Omaha, Nebraska 68106
?
mi
from
Omaha, NE
Click here to add this to my saved trials
1020 Walnut St
Philadelphia, Pennsylvania 19107
(215) 955-6000
Thomas Jefferson University We are dedicated to the health sciences and committed to educating professionals,...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19111
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15213
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Rockford, Illinois 61104
?
mi
from
Rockford, IL
Click here to add this to my saved trials
Saint Louis Park, Minnesota 55416
?
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
450 Serra Mall
Stanford, California 94305
(650) 723-2300
Stanford University Stanford University, located between San Francisco and San Jose in the heart of...
?
mi
from
Stanford, CA
Click here to add this to my saved trials
Toledo, Ohio 43617
?
mi
from
Toledo, OH
Click here to add this to my saved trials
Waukesha, Wisconsin 53188
?
mi
from
Waukesha, WI
Click here to add this to my saved trials
Wauwatosa, Wisconsin 53226
?
mi
from
Wauwatosa, WI
Click here to add this to my saved trials
?
mi
from
West Reading, PA
Click here to add this to my saved trials
Wynnewood, Pennsylvania 19096
?
mi
from
Wynnewood, PA
Click here to add this to my saved trials